We studied expression of vascular endothelial growth factor (VEGF) in paraffin-embedded bone marrow sections obtained from 15 patients with chronic myeloid leukemia (CML) in chronic phase (CP), 3 in accelerated phase (AP), 7 in myeloid blast phase (BP M ), 6 in lymphoid blast phase (BP L ), and in 3 normal bone marrow samples. VEGF expression was determined immunohistochemically by using an anti-VEGF antibody. In CML-CP, the distribution of VEGF showed a pattern similar to that of normal marrow. VEGF was expressed in myeloid progenitors and megakaryocytes and less abundantly in mature granulomonocytic cells, whereas erythroid cells did not stain positively for VEGF. In CML-BP M , myeloblasts expressed substantial amounts of VEGF. By contrast, little if any VEGF was detectable in blast cells in CML-BP L . VEGF messenger RNA (mRNA) was detected in leukemic cells in CML-BP M by reverse transcriptase-polymerase chain reaction, whereas blast cells in CML-BP L did not express substantial amounts of VEGF mRNA. Our data show that VEGF is expressed in immature myeloid cells in CML. The extent of VEGF expression depends on the phase of disease and the cell type involved in disease progression.
Chronic myeloid leukemia (CML) is a myeloproliferative disease in which clonal cells display the 210-kd form of BCR/ABL, an oncoprotein generated by the reciprocal translocation t(9;22). [1] [2] [3] [4] [5] BCR/ABL exhibits constitutive tyrosine kinase activity, leading to its phosphorylation and to activation of multiple signaling pathways. 1, 2, 6 As a result, BCR/ABL leads to increased proliferation and inhibition of apoptosis with consecutive accumulation of leukemic cells in hematopoietic tissues. 1, 2, 6, 7 The natural course of CML can be divided into 3 phases: chronic phase (CML-CP), accelerated phase (CML-AP), and blast phase (CML-BP). 1, 2, 7, 8 In CML-CP, the disease progresses slowly and can be kept under control with cytoreductive drugs. 2, 7 Over time, however, the leukemic (BCR/ABL-positive) cells acquire additional genetic defects responsible for transformation to AP and BP. Such additional gene defects supposedly cooperate with bcr/abl in leukemogenesis and lead to resistance against antileukemic drugs. 1, 6 CML-BP is the terminal phase of disease and resembles acute leukemia. In the majority of patients (70%-80%) a myeloid blast phase (CML-BP M ) occurs. 9, 10 In the remaining patients, blast cells are lymphoid (lymphoid blast phase, CML-BP L ) and of B lineage in the vast majority of the cases. 9, 10 During the past few years a number of attempts have been made to identify disease-related and prognostic factors in CML. [11] [12] [13] Among these factors are hematopoietic cytokines, various pro-oncogenic molecules, tumor suppressor genes, antiapoptotic molecules, and proangiogenic growth regulators. [14] [15] [16] [17] Recent data suggest that vascular endothelial growth factor (VEGF) is overexpressed in patients with CML and has a potential role in the pathogenesis of the disease. [16] [17] [18] [19] [20] In fact, VEGF has been implicated as an essential mediator of leukemia-associated angiogenesis. [16] [17] [18] [19] In addition, this cytokine has been described as a potential autocrine or paracrine growth regulator of leukemic cells in myeloid neoplasms. 21, 22 More recent data suggest that VEGF is produced and secreted in CML cells in a BCR/ABL-dependent manner. [23] [24] [25] Correspondingly, increased levels of VEGF are detectable in serum samples of patients with CML. [17] [18] [19] 26 A correlation between serum VEGF levels and prognostic parameters (age, platelet count, blasts) in CML also has been described. 26 However, little is known about the expression of VEGF in various phases of CML and about the exact distribution of this cytokine in the cellular compartments of leukemic bone marrow. In addition, little is known about the regulation of production of VEGF (including VEGF messenger RNA [mRNA] expression) in bone marrow progenitor cells.
We have recently established a staining protocol for the detection of VEGF in paraffin-embedded bone marrow biopsy sections. 27, 28 In the present study, we applied this protocol to a cohort of patients with CML to study the expression and distribution of VEGF in the bone marrow in various phases of the disease.
Materials and Methods

Patients
A total of 31 patients (9 females; 22 males) with CML were examined. The median age was 54 years (range, 8-82 years). Bone marrow was obtained from the iliac crest after informed consent was given. Of the 31 patients, 15 had CML-CP, 3 had CML-AP, 7 had CML-BP M , and 6 had CML-BP L . Diagnoses were established according to the World Health Organization criteria. 8 Characteristics of the patients are shown in ❚Table 1❚. For control purposes, we examined 3 patients with normal bone marrow (staging of patients with non-Hodgkin lymphoma). 
Immunohistochemical Analysis
Immunohistochemical analysis was performed on paraffin-embedded, formalin-fixed bone marrow sections using the indirect immunoperoxidase staining technique. 27, 28 Endogenous peroxidase was blocked by methanol/hydrogen peroxide. Before staining with polyclonal rabbit anti-VEGF antibody (Santa Cruz, Santa Cruz, CA), sections were pretreated by microwave oven. The anti-VEGF antibody was diluted (1:50) in a 0.05-mol/L concentration of tris(hydroxymethyl)aminomethane-buffered saline (pH 7.5) plus 1% bovine serum albumin and applied for 60 minutes. In select experiments, anti-VEGF was preincubated with a specific (VEGF-related) blocking peptide (Santa Cruz). After washing, slides were incubated with biotinylated goat antirabbit IgG for 30 minutes, washed, and exposed to avidin-peroxidase complex. 3-Amino-9-ethylcarbazole was used as the chromogen. Slides were counterstained in Mayer hemalum.
Determination of Cellular VEGF Levels and VEGF Secretion in CML Cells
In 8 patients with CML (CML-CP, 3; CML-BP M , 3; CML-BP L , 2), cellular levels of VEGF were measured in bone marrow-derived mononuclear cells (MNCs). Bone marrow MNCs were isolated using Ficoll. After isolation, the MNCs were washed in phosphate-buffered saline and lysed in distilled water. After freeze-thawing, cell lysates were subjected to VEGF measurement by enzyme-linked immunosorbent assay (ELISA). Cellular levels of VEGF were calculated from VEGF concentrations in cell lysates and absolute numbers of cells per sample and were expressed in picograms per 10 7 cells.
In 2 patients with CML, isolated bone marrow MNCs were cultured in RPMI 1640 medium (PAA Laboratories, Linz, Austria) supplemented with 10% fetal calf serum (PAA Laboratories) in 5% carbon dioxide at 37°C for 3 weeks. During the culture period, cell-free supernatants and cells were recovered every 4 to 5 days. Lysates of cultured cells were prepared by centrifugation and freeze-thawing.
The levels of VEGF in supernatants and cell lysates were determined by using a commercial ELISA (R&D Systems, Minneapolis, MN). The detection limit of the ELISA amounted to 5 pg of VEGF per milliliter. No crossreactivity with other cytokines was found.
Northern Blot Analysis
For mRNA analysis, peripheral blood MNCs derived from 2 patients with CML-CP and 1 with CML-BP L were used. In 1 CML-CP case, MNCs were cultured in RPMI 1640 medium and 10% fetal calf serum in the presence or absence of imatinib mesylate (STI-571; 1-µmol/L) for 16 hours before RNA isolation. Total RNA was extracted from MNCs using Trizol (Gibco, Carlsbad, CA) according to the manufacturer's instructions. Northern blotting was performed according to a published technique. 23, 29 In the first step, 20 µg of total RNA was sizefractionated on 1.0% formaldehyde-agarose gels and transferred to nylon membranes (Hybond N, Amersham, Aylesbury, England) as described by Chomczynski. 29 Membranes were hybridized in rapid-hyb buffer (Amersham). Hybridization was performed with phosphorus 32-labeled complementary DNA specific for VEGF or β-actin. 23 Labeling was performed using the Megaprime kit (Amersham). Blots were washed in 0.2× standard saline citrate (1× standard saline citrate = 150-mmol/L of sodium chloride and 15-mmol/L of sodium citrate, pH 7.0) with 0.1% sodium dodecyl sulfate at 42°C twice for 30 minutes each time and at 62°C for another 30 minutes. Bound radioactivity was visualized by exposure to Biomax MS film (Kodak, Rochester, NY) at -80°C using intensifying screens (Eastman Kodak, Rochester, NY). Expression levels of mRNA were quantified by densitometry of autoradiograms by using E.A.S.Y. Win32 software (Herolab, Wiesloch, Germany).
Reverse Transcriptase-Polymerase Chain Reaction Analysis
Total RNA was extracted from peripheral blood MNCs obtained from 1 patient with CML-BP L and 1 patient with CML-BP M using the RNeasy Mini Kit (Quiagen, Hilden, Germany). RNA extraction was performed according to the instructions of the manufacturers. One-step reverse transcriptase-polymerase chain reactions (RT-PCR) were performed on total RNA (50 ng per reaction) using the Titan 1-tube RT-PCR system (Roche, Mannheim, Germany) and primers specific for human VEGF 30 (PCR conditions: 31 cycles; annealing temperature, 60°C; product size, 574 base pairs). Equal loading was confirmed by determination of β-actin mRNA levels using published primers 31 (PCR conditions: 23 cycles; annealing temperature, 60°C; product size, 260 base pairs). VEGF and β-actin mRNA expression levels were quantified by densitometry using E.A.S.Y. Win32 software (Herolab).
Results
Immunohistochemical Detection of VEGF in the Bone Marrow in CML-CP
VEGF was detectable in bone marrow sections from all patients with CML-CP. The specificity of the staining reaction could be demonstrated using a VEGF-blocking peptide. In fact, preincubation of the antibody with the blocking peptide resulted in a negative staining result (not shown). In all 7 patients with CML-CP from whom samples were analyzed, almost identical staining results were obtained. In fact, in all patients, the anti-VEGF antibody reacted with immature myeloid progenitors (blast cells), promyelocytes, myelocytes, and megakaryocytes ❚Image 1A❚. Plasma cells also were labeled by the anti-VEGF antibody. By contrast, mature granulocytic cells expressed low levels of VEGF or did not express measurable amounts of VEGF. Erythroid cells were consistently negative for VEGF in all cases (Image 1A).
In the 3 normal bone marrow samples, an almost identical distribution of VEGF in the various hematopoietic cell lineages was found compared with the bone marrow in CML-CP. In particular, the anti-VEGF antibody recognized immature myeloid cells, megakaryocytes, and plasma cells in these cases, whereas mature granulocytic cells and erythroid cells did not stain positively for VEGF. Owing to the myeloid hyperplasia and left shift in CML, the number of VEGF-positive cells was lower in normal bone marrow samples compared with samples from patients with CML-CP. ❚Table 2❚ shows a summary of VEGF-staining results obtained in patients with CML and in normal bone marrow samples.
Immunohistochemical Detection of VEGF in the Bone Marrow in CML-BP
VEGF expression was next analyzed in patients with CML-BP. Seven of these patients had CML-BP M , and 6 had CML-BP L . In patients with CML-BP M , the blast cells in the bone marrow contained variable amounts of VEGF, ranging from low expression ❚Image 1B❚ to strong expression of VEGF ❚Image 1C❚. By contrast, in patients with CML-BP L , the levels of VEGF in the bone marrow were consistently low. In these patients, the majority of blasts did not express detectable amounts of VEGF ❚Image 1D❚ (Table 2) .
Cellular Levels of VEGF in Bone Marrow Cells Derived From Patients With CML
In 8 patients with CML (CML-CP, 3; CML-BP M , 3; CML-BP L , 2), the cellular levels of VEGF were measured by an ELISA. In the 3 patients with CML-CP, the cellular levels of VEGF amounted to 60.7, 260.6, and 67.8 pg/10 7 cells, respectively. The VEGF levels in patients with CML-BP were clearly lower. In the 3 patients with CML-BP M , the levels of VEGF amounted to 5.3, 5.8, and 13.5 pg/10 7 cells, respectively. In both patients with CML-BP L , VEGF levels were less than 5 pg/10 7 cells.
Detection of VEGF in Supernatants of Isolated CML Cells
To confirm the production of the VEGF protein in CML cells, culture experiments were carried out using peripheral blood MNCs obtained from 2 patients with CML-CP. In both cases, the levels of VEGF in the cell-free supernatants increased substantially during a 21-day culture period in the absence of any growth factor ❚Figure 1❚. Cellular levels of VEGF did not change during the culture period (data not shown). These data suggest that CML cells are capable of producing and secreting the VEGF protein in vitro in a factor-independent manner.
Expression of VEGF mRNA in CML Cells
To confirm the production of VEGF in CML cells, Northern blot experiments were performed using RNA of peripheral blood MNCs derived from patients with CML. First, we examined the expression of VEGF mRNA in a patient with CML-CP. Before mRNA isolation, MNCs were cultured in the presence or absence of the BCR/ABL-targeting drug imatinib mesylate. As shown in ❚Image 2❚, unstimulated CML cells expressed substantial amounts of VEGF mRNA. Preincubation of the cells with imatinib mesylate resulted in a substantial decrease in VEGF mRNA expression (Image 2), providing further (indirect) evidence of the expression of cytokine-specific transcripts in clonal (BCR/ABL-positive and, thus, imatinib mesylate-sensitive) cells.
Next, we examined VEGF mRNA expression in leukemic cells in various phases of CML. As expected, the levels of VEGF mRNA were higher in CML-CP than in CML-BP. ❚Image 3A❚ shows a Northern blot experiment performed on MNCs obtained from 1 patient with CML-CP and 1 patient with CML-BP L . To compare the levels of VEGF mRNA expressed in blast cells in CML-BP subvariants, RT-PCR was performed using blast cells from a patient with CML-BP M and blast cells from a patient with CML-BP L . As shown in ❚Image 3B❚, the blast cells from the patient with CML-BP M contained higher levels of VEGF mRNA than those found in blast cells from the patient with CML-BP L . These data confirmed our immunohistochemical staining results and suggest that myeloblasts produce more VEGF than lymphoblasts in CML-BP.
Discussion
VEGF has recently been implicated in the pathogenesis of myeloid neoplasms, including CML. [17] [18] [19] [22] [23] [24] [25] [26] In particular, VEGF might act as a mediator of neoangiogenesis in the leukemic marrow and an autocrine or paracrine growth factor of leukemic cells. 19, 20 In patients with CML, VEGF is highly up-regulated in the bone marrow and in the peripheral blood and might contribute to the pathogenesis of the disease or to disease progression. [17] [18] [19] The present study provides further evidence that leukemic cells in patients with CML express VEGF. Moreover, our data show that expression of VEGF in bone marrow cells varies among patients in various phases of CML.
In a first step, we analyzed the expression of VEGF in leukemic cells in CML-CP at the mRNA and protein levels to define whether the cytokine is produced constantly. Our data suggest that unstimulated CML cells express VEGF mRNA and express and secrete the VEGF protein. The possibility that VEGF was produced by coisolated accessory or residual normal (polyclonal) hematopoietic cells seems unlikely. First, the purity of isolated leukemic (over nonhematopoietic) cells was more than 99%. Moreover, the expression of VEGF decreased substantially after exposure of cells to the BCR/ABL-targeting drug imatinib mesylate. All in all, these data provide further evidence that CML cells produce, express, and secrete VEGF.
We next examined the distribution of VEGF in the various cellular compartments of the leukemic bone marrow.
As assessed by immunohistochemical analysis, immature myeloid cells and megakaryocytes expressed substantial amounts of VEGF in all patients, whereas erythroid cells were negative for VEGF, thus resembling the distribution of VEGF in the normal bone marrow and, to some degree, also in the bone marrow in patients with acute myeloid leukemia (AML). 28 Based on these observations, it is tempting to speculate that the expression of VEGF in leukemic cells is regulated in a way similar to that in normal myeloid cells. However, the expression of VEGF in CML cells is, at least in part, under the control of the bcr/abl oncogene. 23, 24 In fact, BCR/ABL up-regulates VEGF expression in Ba/F3 cells. 23 Moreover, the BCR/ABL-targeting drug imatinib mesylate was found to down-regulate the expression of VEGF mRNA in isolated CML cells in the present study, and a similar observation was made with K562 cells by Ebos et al. 25 On the other hand, mature granulocytic and erythroid cells, both of which are considered to be clonal and to display BCR/ABL in patients with CML, are negative for VEGF. This observation might have several explanations. First, BCR/ABL might only be capable of promoting VEGF production in precursor cells that are programmed already to produce VEGF or actually produce (lower levels of) this cytokine. An alternative explanation would be that BCR/ABL is less active as a VEGF-inducing factor in mature granulocytes and erythroid cells compared with immature cells. Such a hypothesis would be in line with the notion that CML granulocytes behave similarly compared to normal cells (undergo apoptosis) and with the phenomenon that despite myeloid hyperplasia, the erythroid compartment in CML remains normal without leukemic expansion. Recent data suggest that VEGF has a pathogenetic role as an autocrine or paracrine growth regulator and a mediator of disease-associated angiogenesis in patients with myeloid leukemias. [17] [18] [19] [20] 22, 32 Likewise, leukemic cells in myeloid leukemias, including CML, might express receptors for VEGF. 32 In addition, the expression and production of VEGF in leukemic cells might correlate with disease progression. 26 Therefore, we compared the expression of VEGF in leukemic cells in various phases of CML. The observation that VEGF levels were clearly lower in most patients with CML-BP than in patients with CML-CP was an unexpected finding. In fact, in most patients with AML (except AML-M0), myeloblasts express substantial amounts of VEGF. 28 We therefore analyzed subvariants of CML-BP. In these analyses, we found that the levels of VEGF in blasts from patients with CML-BP L were invariably low, whereas in patients with CML-BP M , VEGF levels varied. In particular, in some of these patients, blast cells clearly expressed VEGF, whereas in other cases, blast cells expressed only low or moderate levels of VEGF. In all BP cases examined, however, cellular levels of VEGF determined by ELISA were lower than those measured in patients with CML-CP. The decreased expression of VEGF in CML-BP compared with CML-CP and the decreased expression of VEGF in CML-BP L compared with CML-BP M were also demonstrable at the mRNA level.
The particularly low expression of VEGF in blast cells in CML-BP L is a remarkable phenomenon. In fact, these patients may have a slightly better prognosis than patients with CML-BP M . 2 The biochemical basis of the loss of VEGF in these cells (compared with CML-CP and CML-BP M ) remains unknown. One explanation would be that the lymphoid lineage is less sensitive to BCR/ABL-mediated induction of the VEGF gene compared with myeloid progenitor cells. Alternatively, these cells acquire recurrent genetic defects (in addition to bcr/abl) that counteract VEGF expression, enhance its degradation, or promote its release from leukemic cells.
Another interesting phenomenon observed was the variability in expression of VEGF in myeloblasts among patients with CML-BP M . A number of different explanations might be considered: first, CML is a stem cell disease, and transformation to the blast phase might occur at several different stages of stem cell differentiation. 1, 2, [8] [9] [10] If so, the levels of VEGF may vary in blast cells depending on the maturation stage of the stem cell involved in progression. Likewise, the blast cells in AML-M0, an AML subtype that reflects the most immature stage of myeloid stem cell development, were found to be virtually negative for VEGF, whereas AML blasts in all other French-American-British categories clearly expressed VEGF. 28 In view of this notion, the blast cell populations that expressed only low levels of VEGF in CML-BP M also might represent a very immature (stem cell) stage of myelopoiesis. Another possibility would be that the differential expression of VEGF in myeloblasts in patients with CML-BP M is due to different genetic defects. Thus, during progression to CML-BP, many different genes can be affected, and some of them might be involved in the regulation of expression (degradation or release) of VEGF in myeloid cells. 1, 2, 6, 7, 12, 15 In summary, our data show that VEGF is expressed in immature myeloid cells in patients with CML and that VEGF expression varies among different phases of the disease. Most important, VEGF is expressed in leukemic cells in all patients with CML-CP and is expressed variably in blast cells in cases of CML-BP M , but it does not seem to be expressed in lymphoid blasts in patients with CML-BP L . The pathogenetic significance of these observations remains to be determined.
